AB&B BIO-TECH-B (02627) saw its shares rise more than 7% during the late trading session. At the time of writing, the stock was up 7.31%, trading at HK$56.5, with a turnover of HK$87.528 million. The surge follows an announcement made after the market close on March 6 by the Shanghai and Shenzhen stock exchanges, which revealed an adjustment to the list of eligible stocks under the Hong Kong Stock Connect scheme. According to the announcement, AB&B BIO-TECH-B has been added to the list, with the changes taking effect from March 9. Notably, on March 4, the company announced that its self-developed monkeypox mRNA vaccine had received clinical trial approval from the U.S. Food and Drug Administration. Public information indicates that this vaccine is the first of its kind in China and the third globally to receive such approval for clinical trials. The FDA's clearance not only affirms the company's product development capabilities but also represents international recognition of AB&B BIO-TECH-B's mRNA technology platform.